Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Myelodysplastic syndromes (MDS) are heterogeneous bone marrow diseases with varying risk levels.
• MDS can progress to acute myeloid leukemia.
• Flow cytometry (FCM) is increasingly recognized for its role in MDS management.

Purpose of the Study:

• To review the diagnostic, prognostic, and therapeutic value of FCM in MDS.
• To highlight FCM's utility in distinguishing clonal from non-clonal cytopenias.
• To assess FCM's potential in predicting treatment response.

Main Methods:

• Review of current scientific literature on FCM in MDS.
• Analysis of FCM's sensitivity in detecting dysplasia across cell lineages.
• Evaluation of FCM's correlation with prognosis and treatment outcomes.

Main Results:

• FCM demonstrates high sensitivity in detecting dysplasia in myelo-/monocytic and erythroid lineages.
• FCM aids in differentiating clonal from non-clonal causes of cytopenias.
• FCM shows promising utility in predicting treatment response in MDS.

Conclusions:

• FCM is an essential tool for the standard diagnosis of suspected MDS.
• FCM assists in identifying multi-lineage dysplasia alongside cytomorphology.
• FCM is ready for general application in MDS diagnostics and management.